Currently, an estimated 5.4 million people have Alzheimer’s Disease and as the baby boomers reach the age of 65, their risk of developing Alzheimer’s Disease considerably increases.
The A4 Study, shorthand for the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Study, is studying a new treatment that may reduce the impact of a protein known as “beta amyloid,” which forms plaque in the brain. Scientists believe that the abnormal accumulation of the amyloid in the brain may play a key role in the development of Alzheimer’s Disease. The A4 study is seeking individuals between 65 and 85 who have normal thinking and memory function, no outward signs of Alzheimer’s Disease, but may be at a potentially high risk of developing the disease.
The researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health along with 60 centers in the United States, Canada, and Australia are actively engaged in this clinical trial funded by National Institute on Aging.
“We are reaching out to our community and welcoming our volunteers to join this exciting study,” said Dr. Kate Zhong, Senior Director of Clinical Research and Development for Cleveland Clinic Lou Ruvo Center for Brain Health. “This study is a potential game changer. It will help us to find treatment to delay the onset of and ultimately prevent Alzheimer’s Disease altogether. Our volunteers have a real chance to improve the quality of their lives and assist in making medical history,” Dr. Zhong said.
By investing an hour at the clinic once a month for three years, participants can help to advance science, find a treatment, and eradicate Alzheimer’s Disease for future generations.